BioMarin Pharmaceutical | BMRN - Current Liabilities

Stock Price
56.38
Daily Change
-1.39 -2.41%
Monthly
-0.74%
Yearly
-33.14%
Q3 Forecast
57.29

BioMarin Pharmaceutical reported $684.25M in Current Liabilities for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 7.46B
Cash and Equivalent USD 1.21B
Cost of Sales USD 154.94M
Current Assets USD 3.81B
Current Liabilities USD 684.25M
Debt USD 603.87M
EBIT USD 276.89M
EBITDA USD 295.45M
Employees 3.04K
EPS Earnings Per Share USD 1.44
Equity Capital and Reserves USD 6.03B
Gross Profit on Sales USD 670.47M
Interest Expense on Debt USD 2.68M
Interest Income USD 18.83M
Loan Capital USD 596.16M
Market Capitalization USD 10.75B
Net Income USD 240.53M
Operating Expenses USD 548.52M
Operating Profit USD 276.89M
Ordinary Share Capital USD 192M
PE Price to Earnings USD 15.13
Pre-Tax Profit USD 297.87M
Sales Revenues USD 825M
Selling and Administration Expenses USD 232.28M
Stock USD 1.34B
Trade Creditors USD 684.25M
Trade Debtors USD 855.86M

Current Liabilities Change Date
Acadia Pharmaceuticals USD 330.02M 27.49M Jun/2025
Agios Pharmaceuticals USD 70.41M 18.04M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 225.22M Jun/2025
Amgen USD 20.48B 2.53B Jun/2025
Bayer EUR 29.78B 1.82B Jun/2025
Biogen USD 3.18B 2.11B Jun/2025
BioMarin Pharmaceutical USD 684.25M 56.03M Jun/2025
Gilead Sciences USD 11.19B 1.15B Jun/2025
Incyte USD 1.28B 608.18M Jun/2025
Insmed USD 311.68M 72.45M Jun/2025
Ionis Pharmaceuticals USD 897.24M 646.94M Jun/2025
Moderna USD 1.57B 32M Jun/2025
Neurocrine Biosciences USD 546.3M 23.4M Jun/2025
PTC Therapeutics USD 627.81M 32.42M Jun/2025
Regeneron Pharmaceuticals USD 3.67B 100.4M Jun/2025
Roche Holding CHF 27.02B 424M Dec/2024
Sanofi EUR 29.06B 103M Jun/2025
Sarepta Therapeutics USD 919.95M 314.36M Jun/2025
Ultragenyx Pharmaceutical USD 293.24M 1.58M Jun/2025
United Therapeutics USD 527.1M 194.4M Jun/2025
Vertex Pharmaceuticals USD 4.14B 355.2M Jun/2025